<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01570101</url>
  </required_header>
  <id_info>
    <org_study_id>CP-10763-01</org_study_id>
    <nct_id>NCT01570101</nct_id>
  </id_info>
  <brief_title>European Sapheon™ Closure System Observational ProspectivE (eSCOPE) Study</brief_title>
  <acronym>eSCOPE</acronym>
  <official_title>Post Market Study - &quot;European Observational Study of the Sapheon™ Closure System for the Definitive Treatment of Incompetent Great Saphenous Veins: A Prospective Single Arm Multicenter Clinical Observational Study&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective for this clinical study is to assess the role of the CE Marked Sapheon&#xD;
      Closure System in closure of incompetent great saphenous veins &quot;GSV&quot; in a routine clinical&#xD;
      setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post market, observational study of closure of the great saphenous vein &quot;GSV&quot;.&#xD;
      Efficacy and safety (adverse events) will be compared to appropriate literature reports to&#xD;
      determine if the results of the treatment of reflux disease with the Sapheon Closure System&#xD;
      are consistent with or better than the expectations of the medical community for alternative&#xD;
      treatments, specifically Laser Thermal Ablation and Radiofrequency Ablation. Additional&#xD;
      comparison points may include measurements of pain and/or length of time to return to work.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative Duplex Ultrasound</measure>
    <time_frame>Immediately Post-procedure</time_frame>
    <description>The Primary endpoint is a change in duplex ultrasound immediately post-procedure as compared to the pre-procedure duplex ultrasound, proving great saphenous vein closure with lack of pathological reflux.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Immediately post-op through 6 month Follow-up &quot;FU&quot;</time_frame>
    <description>The Secondary endpoint is safety, reflected by the rate of occurrence of all adverse events (procedure and non-procedure related; serious and non-serious).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Venous Insufficiency of Leg</condition>
  <arm_group>
    <arm_group_label>CE Marked Sapheon Closure System in GSV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CE Marked Sapheon Closure System in closure of incompetent great saphenous veins &quot;GSV&quot; in a routine clinical setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CE Marked Sapheon Closure System</intervention_name>
    <description>CE Marked Sapheon Closure System in closure of incompetent great saphenous veins &quot;GSV&quot; in a routine clinical setting.</description>
    <arm_group_label>CE Marked Sapheon Closure System in GSV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and ≤ 70 years of age.&#xD;
&#xD;
          -  Symptomatic primary Great Saphenous Vein &quot;GSV&quot; incompetence diagnosed by clinical&#xD;
             symptoms, with or without visible varicosities, and confirmed by duplex ultrasound&#xD;
             imaging.&#xD;
&#xD;
          -  CEAP classification of C2, C3 or C4.&#xD;
&#xD;
          -  Ability to walk unassisted.&#xD;
&#xD;
          -  Ability to attend follow-up visits.&#xD;
&#xD;
          -  Ability to understand the requirements of the study and to provide written informed&#xD;
             consent.&#xD;
&#xD;
          -  &quot;GSV&quot; on standing pre-procedure Doppler Ultrasound ≥3mm and ≤10mm (maximum diameter).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt; 1 year.&#xD;
&#xD;
          -  Regular pain medication.&#xD;
&#xD;
          -  Anticoagulation including Heparin or Coumadin.&#xD;
&#xD;
          -  Previous Deep Vein Thrombosis &quot;DVT&quot;.&#xD;
&#xD;
          -  Previous superficial thrombophlebitis in &quot;GSV&quot;.&#xD;
&#xD;
          -  Previous venous treatment on target limb.&#xD;
&#xD;
          -  Known Hyper-coagulable disorder.&#xD;
&#xD;
          -  Conditions which prevent routine vein treatment like:&#xD;
&#xD;
               -  Acute disease,&#xD;
&#xD;
               -  Immobilization or inability to ambulate, and&#xD;
&#xD;
               -  Pregnancy.&#xD;
&#xD;
          -  Tortuous &quot;GSV&quot;, which in the opinion of the Investigator will limit catheter&#xD;
             placement. (no 2 primary access sites allowed).&#xD;
&#xD;
          -  Incompetent ipsilateral small saphenous or anterior accessory great saphenous vein.&#xD;
&#xD;
          -  Known sensitivity to the cyanoacrylate &quot;CA&quot; adhesive.&#xD;
&#xD;
          -  Current participation in another clinical study involving an investigational agent or&#xD;
             treatment, or within the 30 days prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Proebstle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik Proebstlé</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aareknudeklinikken</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologikum</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Proebstle</name>
      <address>
        <city>Mannheim</city>
        <zip>D - 68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Oosterawal</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Countess of Chester Hospital NHS Foundation Trust</name>
      <address>
        <city>Chester</city>
        <zip>CH2 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Whiteley Clinic</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2012</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venous Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

